Abingworth closes latest life sciences fund on $465M
February 4, 2021
London-based life sciences investor Abingworth has closed its eighth transatlantic venture fund on $465 million, exceeding its $375 million target. The vehicle will be used for seed and early-stage deals, as well as investments in public equities, with companies typically receiving between $15 million and $30 million. Abingworth Bioventures 8 has already been used to back Atsena Therapeutics, Reneo Pharmaceuticals and Vera Therapeutics.